Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Amanda E Marinoff und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Receptors, Thrombopoietin, Thrombocytopenia, Hematologic Neoplasms, Thrombopoietin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Thrombopoietin receptor agonists (TPO‐RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy‐induced thrombocytopenia in adults. However, data regarding their safety and efficacy in pediatric, adolescents, and young adult (AYA) patients with hematologic malignancies are limited.
Methods
We retrospectively identified 15 pediatric and AYA patients aged 25 years or younger with hematologic malignancies treated with a TPO‐RA at UCSF Benioff Children's Hospitals between 2015 and 2023. Platelet counts and transfusion requirements were compared before and after TPO‐RA therapy.
Results
The median age at TPO‐RA initiation was 16 years (range: 7–25 years). Nine patients (60%) had a history of bleeding or comorbidity that predisposed to severe bleeding risk. Eleven patients received romiplostim and four patients received eltrombopag. The median platelet count significantly increased from 24 × 10 9 /L at baseline to 54 × 10 9 /L after 3 weeks of any TPO‐RA therapy ( p = 0.029). Monthly platelet transfusion requirements significantly decreased from a median of 15 to two units after TPO‐RA therapy ( p = 0.007). Fourteen of the 15 patients (93%) achieved a sustained platelet count >50,000/µL within 8 weeks, with a median time to response of 3 weeks. No TPO‐RA‐related adverse events were observed.
Conclusion
TPO‐RAs were effective in managing refractory thrombocytopenia in pediatric and young adult patients being treated for hematologic malignancies, with a favorable safety profile, even among patients with multiple comorbidities. These findings warrant further investigation through prospective clinical trials to confirm efficacy and establish clinical guidelines for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
- VinUniversity (Trường Đại học VinUni), Vinhomes Ocean Park, Gia Lâm, Vietnam.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Amanda E Marinoff, Beth Apsel Winger, Elliot Stieglitz
Förderung
- NCI NIH HHS
Zitieren
APA
Marinoff, A. E., Thrall, A., Aaronson, K., Braun, B. S., Castellanos, M., Chu, J., Hermiston, M., Huang, B. J., Levinson, A., Southworth, E., Winger, B. A., Olshen, A., & Stieglitz, E. (2025). Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31528
Vancouver
Marinoff AE, Thrall A, Aaronson K, Braun BS, Castellanos M, Chu J, et al. Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31528
BibTeX
@article{Marinoff2025,
author = {Marinoff, Amanda E and Thrall, Allyson and Aaronson, Kathryn and Braun, Benjamin S and Castellanos, Maria and Chu, Julia and Hermiston, Michelle and Huang, Benjamin J and Levinson, Anya and Southworth, Erica and Winger, Beth Apsel and Olshen, Adam and Stieglitz, Elliot},
title = {Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31528}
}
EUVIMED